Home › Upcoming votes › Elicio Therapeutics, Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Elicio Therapeutics, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of Directors Director election |
Board | For | 2 nominees; support 95% to 99.6% |
| 2 | Ratification of Selection of Independent Registered Public Accounting Firm Auditor |
Board | For | 99.7% support |
From Elicio Therapeutics, Inc.’s Form 8-K, filed May 20, 2025, for the meeting held May 19, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Karen J. Wilson | 95% | — |
| Elect Director: Robert R. Ruffolo, Jr., Ph.D., FCPP | 99.6% | — |
| 2. To ratify the selection by the Audit Committee of the Board of Directors of Baker Tilly US, LLP as the independent registered public acco | 99.7% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.